Chagas disease is caused by infection with the protozoan Trypanosoma cruzi. CD8 T-lymphocytes help to control infection, but apoptosis of CD8 T cells disrupts immunity and efferocytosis can enhance parasite infection within macrophages. Here, we investigate how apoptosis of activated CD8 T cells affects M1 and M2 macrophage phenotypes. First, we found that CD8 T-lymphocytes and inflammatory monocytes/macrophages infiltrate peritoneum during acute T. cruzi infection. We show that treatment with anti-Fas ligand (FasL) prevents lymphocyte apoptosis, upregulates type-1 responses to parasite antigens, and reduces infection in macrophages cocultured with activated CD8 T cells. Anti-FasL skews mixed M1/M2 macrophage profiles into polarized M1 phenotype, both in vitro and following injection in infected mice. Moreover, inhibition of T-cell apoptosis induces a broad reprogramming of cytokine responses and improves macrophage-mediated immunity to T. cruzi. The results indicate that disposal of apoptotic CD8 T cells increases M2-macrophage differentiation and contributes to parasite persistence.
Chagas disease, caused by the pathogenic protozoan Trypanosoma cruzi, is endemic in Latin America, despite efforts to control insect vector and transmission. 1 T. cruzi parasites infect virtually any cell, reaching the cytoplasm, where replication ensues, followed by cell death and spread of infective parasites. Most patients remain asymptomatic, but persistence of parasites often results in chronic disease, affecting the peripheral nervous system or the heart of patients. 2, 3 Cellular and humoral immune responses overcome acute infection, but fail to eliminate T. cruzi and infected cells. 4 No vaccine or effective drug for treating established disease is available. 3 The protozoan T. cruzi is equipped with a molecular apparatus that triggers multiple Toll-like receptors and induces innate immunity. In particular, macrophages have a critical role as host cells, antigen-presenting cells, and effectors for parasite killing. [5] [6] [7] [8] Depending on stimuli, macrophages can express distinct activation phenotypes and effects on infection. M1/classically activated/M (LPS+IFN-γ) macrophages usually produce IL-12 and NO for killing of intracellular pathogens, whereas alternatively activated macrophages, belonging to the M2 spectrum, help tissue repair and actually promote infection and tumor growth. [9] [10] [11] [12] T cells as well as antibodies are required to control infection. [13] [14] [15] CD8 T cells eliminate cells harboring parasites in the cytoplasm, whereas both CD4 and CD8 T cells produce IFN-γ and activate macrophages to restrain infection. 16, 17 Effector T-lymphocytes also promote immunopathology in the heart. 18, 19 Conversely, regulatory mechanisms, provided by cytokines and apoptosis of effector cells, dampen inflammation and prevent pathology, but might contribute for parasite persistence. 20, 21 Lymphocytes undergo apoptosis in the course of T. cruzi infection, negatively affecting T-cell expansion, 22, 23 B-cell response, 24 parasite killing by classically activated macrophages, 23, 25 and CD8 T-cell-mediated immunity. 26, 27 Furthermore, uptake of apoptotic cells promotes infection within macrophages, through production of prostaglandin E-2 (PGE-2), TGF-β, and polyamines, 28 features associated with M2/alternatively activated macrophages. 9 By contrast, blockade of PGE-2 production or inhibition of lymphocyte apoptosis by caspase inhibitors reduces parasite growth in vitro and parasitemia. 28, 29 Therefore, apoptosis and efferocytosis stand as potential therapeutic targets. 20, 30, 31 However, it remains unknown whether efferocytosis affects M1/M2 macrophage polarization under the inflammatory setting of infection.
We investigated the molecular mechanisms underlying T-cell apoptosis in T. cruzi infection and found functional expression of both Fas (CD95) and Fas ligand (FasL), 23, 26 caspase-8 activity, and activation of effector caspase-3 29, 32 in T cells from T. cruzi-infected mice. To prevent apoptosis during acute infection, we used both pharmacological approaches and apoptosis-defective mouse models. 23, 26, 29, 32 However, intrinsic defects of immune responses have precluded accurate interpretations of immune outcomes in FasL-mutant mice 23 or in mice expressing the caspase-8 inhibitor viral-FLIP (viral FLICE/caspase-8 inhibitory protein) in T cells. 32 So far, the general caspase inhibitor zVAD and the antagonist anti-FasL mAb effectively inhibited apoptosis and potentiated immunity to T. cruzi infection. 26, 29 CD8, but not CD4, T cells seem to be preferential targets for early effects of apoptosis inhibition in acute infection, based on the earlier kinetics of CD8 T-cell activation and higher Fas expression. 26, 29 Both treatments improved CD8 T-cell survival, macrophage activation, and parasite control in infected mice. 26, 29 The interactions between CD8 T cells and macrophages have not been fully explored and might be crucial to explain effective immunity induced by inhibition of apoptosis. Moreover, it is worth investigating how activated and apoptotic CD8 T cells affect distinct phenotypes of macrophages during infection. By using primary cultures of CD8 T cells and macrophages from infected mice, we recapitulated most features observed in vivo upon inhibition of apoptosis. As assessed by in vitro and in vivo approaches, inhibition of T-cell apoptosis affects the outcome of CD8 T-cell-macrophage crosstalk to reprogram the immune response to T. cruzi infection.
Results

CD8
T cells and monocytes repopulate peritoneal cavity in T. cruzi infection. We used BALB/c mice infected with chemically derived metacyclic trypomastigotes of the Dm28c T. cruzi clone, as a validated experimental model of Chagas disease. 33 Parasitemia peaks~3 weeks after infection and immune responses and inflammation in the heart reproduce features of T. cruzi infection induced by insect-derived metacyclic parasites. 33 In addition, CD8 T cells predominate in heart inflammation, 33 as observed in human patients. 34 We assessed the phenotype of peritoneal exudate cells (PECs) during acute infection and found that about 20-40% of PECs are CD8 T cells (Figure 1a) , whereas CD4 + cells represent only 5% of PECs in both normal and infected mice (not shown). Absolute numbers of CD8 T cells also increase during infection (Figure 1b ). CD8 T cells represent an important source of IFN-γ, as detected in peritoneal exudates from infected mice ( Figure 1c ) and in PECs stimulated with a T. cruzi antigen (Ag; Tzelepis et al. 35 ) (Supplementary Figure S1 ). Although 30-50% of PECs from normal mice express the F4/80 macrophage marker at high levels, only 10-20% of PECs from infected mice express F4/80 at intermediate levels (F4/80 int ) (Figure 1a ). By contrast, 30-40% of PECs from infected, but not normal, mice bear the Ly6C marker of inflammatory monocytes/macrophages (Figure 1a ). Absolute numbers of monocytes (Figure 1b ), but not F4/80 + macrophages (not shown), also increase upon infection. F4/80 int macrophages from infected mice seem to be derived from Ly6C + monocytes, instead of residual resident macrophages. Therefore, inflammatory monocytes/ macrophages comprise about 40-60% of PECs, which adhere to culture plates and acquire F4/80 int ( Figure 2d ). About 90% of adherent cells are F4/80 int and CD11b-double positive macrophages.
Macrophages from infected mice express M1 and M2 phenotypes. To address the functional phenotype of macrophages, we measured the expression of IL-12p35 and macrophage galactose-type lectin-1 (MGL1, CD301a) 36 as surrogate M1 and M2 markers. Although most macrophages from normal mice express MGL1, IL-12p35 and MGL1 defined two subsets in macrophages from infected mice (Figure 1d ). In addition, macrophages from normal mice are more permissive to parasite infection than macrophages from infected mice (Figure 1f) . Interestingly, we detected MGL1 + macrophages associated with cell debris from apoptotic CD8 T cells in PECs from infected mice (Figure 1e and Supplementary Figure S2) . Accordingly, 20-30% of peritoneal CD8 T cells undergo apoptosis during acute infection (not shown) and up to 40% of F4/80 macrophages bear intracellular CD8 + events (Supplementary Figure S2) . These results suggest that the development of functional phenotypes by macrophages is under the influence of activation by type-1 cytokines versus suppression by apoptotic cells.
Blockade of FasL affects the crosstalk between T cells and macrophages. We took advantage of the presence of both CD8 T cells and monocytes/macrophages in the peritoneum of infected mice to investigate the interactions between CD8 T cells and macrophages. We hypothesized that the presence of apoptotic cells could counterbalance macrophage activation and affect immunity to T. cruzi infection. We previously reported that efferocytosis enhances parasite growth within macrophages from T. cruzi-infected mice. 28 To evaluate how apoptosis of activated T cells affects macrophage phenotype, we treated cultures with the neutralizing anti-FasL or control IgG mAb (Figure 2a ). Anti-FasL increased NO responses, but did not improve macrophage viability (Figure 2b and Supplementary Figure S3) . We also used plate-bound anti-CD8 to obtain CD8 T-cell enriched PECs from infected mice (70-80% from culture supernatants). Strikingly, treatment with anti-FasL induced NO in CD8 T-cell enriched cultures, both in the presence and absence of Ag stimulation (Figure 2b , lower panels). Anti-FasL potentiated IL-12 and TNF-α, but not IFN-γ response in CD8 T-cell enriched cultures (Figure 2c ). Treatment with anti-FasL also increased production of NO ( Figure 2b ) and of type-1 cytokines (Figure 2c ) in anti-CD3-activated cultures. Finally, anti-FasL reduced MGL1 expression in F4/80 + macrophages (Figures 2d and e) . Therefore, treatment of primary cultures of peritoneal lymphocytes and macrophages with anti-FasL promoted M1-macrophage phenotype, but restrained M2-macrophages.
Apoptosis in cocultured CD8 T cells disables macrophagemediated immunity. We investigated whether or not T-cell apoptosis affects macrophage activation, by coculturing macrophages with purified/splenic CD8 T cells from infected mice (Figure 3a) . For infected cocultures, PECs from infected mice were carefully washed to remove non-adherent cells To rule out the effects of parasites on cytokine responses, we further assessed treatment with anti-FasL to prevent apoptosis in cocultures that were not exposed to T. cruzi in vitro (Figure 5a ). Different from infected cocultures, type-1 cytokines were at basal levels in unstimulated cocultures (Figure 5b) . Nonetheless, secretion of CXCL9, TNF-α, and G-CSF increased upon anti-CD3 stimulation (Figure 5b) . Similarly, IL-1β, IL-3, IL-10, IL-13, and GM-CSF were upregulated in activated cocultures. Treatment with anti-FasL reduced the levels of IL-1β, IL-3, IL-13, and GM-CSF, but increased CXCL9 secretion (Figure 5b ). Therefore, activation-induced T-cell apoptosis induces macrophages to express an M2-like phenotype that is unable to control T. cruzi infection.
Anti-FasL reduces M2 macrophages in T. cruzi infection.
We investigated whether treatment in vivo with anti-FasL would be effective enough to modulate macrophage phenotype in the activated setting of infection. We evaluated macrophage phenotype 3 days after a single intraperitoneal injection of anti-FasL in infected mice (Figure 6a ). Compared with mice that received control IgG, mice treated with antiFasL showed increased production of G-CSF, but reduced secretion of IL-1β, IL-3, IL-10 ( Figure 6b ), and expression of the M2 marker MGL1 in F4/80 + macrophages (Figure 6d ). Moreover, spontaneous NO production increased in 24 h cultured macrophages, whereas parasite growth decreased in macrophages from mice treated with anti-FasL (Figure 6c) . Therefore, treatment with anti-FasL replaced mixed M1/M2 cells with effector M1 macrophages in infected mice. These results indicate that the blockade of lymphocyte apoptosis by anti-FasL improves macrophage-mediated immunity, but do not rule out the inhibition of apoptosis in other cells or other possible effects of blocking FasL during infection.
Caspase inhibition increases M1/M2 macrophage ratio. We used the general caspase inhibitor zVAD.fmk to target intracellular caspases. 29 Treatment with zVAD reduces caspase-3 activation and apoptosis in CD8 T cells from infected mice (Silva et al. 29 and data not shown). Moreover, pretreatment with zVAD prevented efferocytosis of CD8 T cells by cocultured macrophages (Supplementary Figure S2) . To evaluate how blockade of T-cell apoptosis affects macrophage phenotype, we used in vitro and in vivo approaches (Figures 7a and b) . First, plate-bound anti-CD3 captured (and activated) peritoneal T cells together with adherent PECs. Then, we added zVAD or DMSO to these primary cultures of T cells and macrophages or to macrophage cultures (Figure 7a ). Compared with control diluent (DMSO), treatment with zVAD reduced MGL1 expression and doubled the IL-12/MGL1 ratio in F4/80 + macrophages from activated cultures (Figure 7a) . Therefore, treatment of activated cultures of peritoneal lymphocytes and macrophages with zVAD altered macrophage phenotype. We did not find significant effects of zVAD on macrophages alone. For in vivo experiments, splenic T cells (both CD4 and CD8 T cells at a 1:1 ratio) from infected mice were first stimulated with anti-CD3 in the presence of zVAD or DMSO for 4 or 24 h (for apoptosis assays, Figure 7c (Figure 8c) . Therefore, T-cell apoptosis has a broad effect on macrophage functional phenotype and we were able to restore macrophagemediated immunity by using strategies that prevent T-cell apoptosis both in vitro and in vivo.
Discussion
Here, we addressed how the interactions between macrophages and CD8 T cells affect macrophage phenotype and ability to fight parasite infection. We found that FasL-mediated apoptosis of CD8 T cells induces a broad reprogramming of macrophage responses and is a promising target for upregulation of immune responses to infection. We show that interventions with agents that block T-cell apoptosis and efferocytosis (i.e., anti-FasL or zVAD) restore macrophagemediated immunity.
Previously, we used earlier and repeated injections of antiFasL or zVAD, which improved both lymphocyte and macrophage immune responses, and reduced parasitemia.
26,29
Here we tested a delayed and shorter treatment during acute infection, by the timing that CD8, but not CD4, T cells reach inflammatory macrophages in peritoneal cavity. Inflammatory macrophages from infected mice express Ly6C, a monocyte marker also found in immature myeloid cells from the hearts of T. cruzi-infected mice. 37 Therefore, during acute infection, peritoneal macrophages bear features of immature myeloid cells, and only a fraction of PECs express F4/80. Upon adherence, PECs from infected mice lose Ly6C and acquire F4/80 int expression, along with M1 (IL-12) and M2 (MGL1) markers. Nonetheless, primary cultures of macrophages and peritoneal CD8 T cells treated with anti-FasL or zVAD had reduced M2 and increased M1 phenotype. Moreover, cotreatment with anti-FasL exacerbated type-1 responses to both anti-CD3 and parasite Ag.
In cultures of macrophages and splenic CD8 T cells from infected mice, macrophages express NO-producing M1 phenotype and parasite killing. By contrast, activation with anti-CD3 induced apoptosis of CD8 T cells, reduced NO production, and markedly increased the number of parasites, in spite of higher levels of IFN-γ in cocultures. Importantly, co-treatment with anti-FasL improved recovery of viable CD8 T cells and NO production and helped macrophages to control parasite infection. Therefore, increased parasite replication correlated with the onset of apoptosis in CD8 T cells.
Next, we focused on the cytokines modulated by both anti-CD3 and anti-FasL. We found that activation and treatment with anti-FasL led to a broad reprogramming of macrophage response. Anti-FasL upregulated the proinflammatory cytokines IL-6 and CXCL9, but reduced IL-1β, IL-3, IL-13, and GM-CSF. Although the production of IL-1β might help immunity to T. cruzi, 38 IL-1β secretion did not correlate with NO production or with parasite killing in cocultures. By contrast, parasite growth correlated with production of IL-3, IL-13 (along with IL-10), and GM-CSF, which are potential parasite promoters, either by inducing PGE-2 39 and arginase 40 or by directly affecting parasite growth, 25 features associated with M2 macrophages. Similarly, M2 macrophages induced in the absence of IL-12 promote infection with T. cruzi. 10 Therefore, by blocking apoptosis of CD8 T cells in cocultures, treatment with anti-FasL restricted an M2-like phenotype and parasite growth and increased NO and other M1 features. Similarly, short-term treatment with anti-FasL in vivo reduced M2 responses, but improved parasite killing by macrophages. Therefore, the blockade of lymphocyte apoptosis with antiFasL or zVAD correlates with upregulated M1/M2 ratio and promotes macrophage-mediated immunity. Furthermore, based on the myriad of cytokines and chemokines 11 involved, it could have a broad impact on immune responses.
To our knowledge, we are the first to show that apoptosis of activated CD8 T cells directly affects the macrophage phenotype and is a potential target for improvement of immunity. Although both zVAD and anti-FasL were effective to boost immunity, as opposed to caspase inhibition, the Fas-death pathway stands as a more selective target. This is important to prevent potential side effects of blocking apoptosis or efferocytosis, such as breaking self-tolerance and regulation of immune responses, disrupting tissue repair or affecting immunity to tumors. [41] [42] [43] By contrast, treatment with anti-FasL might affect apoptosis during ongoing immune responses that lead to upregulation of FasL. Nonetheless, other direct or indirect effects of anti-FasL on macrophage activation 44 or death 45 could not be excluded, and potential increase of subsequent Th1 and Th2 responses 23, 26 should be taken into account.
Recently, Vasconcelos et al. 27 showed that the proapoptotic phenotype of Ag-specific CD8 T cells expressing higher levels of Fas correlates with defective immune responses to T. cruzi infection. Moreover, a virus vaccine expressing a parasite Ag prevented the development of proapoptotic CD8 T cells and promoted immunity, comprising both cytotoxic and cytokineexpressing CD8 T cells. 27 Based on these and previous findings, we consider two major, but not exclusive, hypotheses to explain modulation of parasite infection by treatment with anti-FasL. First, by preventing CD8 T-cell death, antiFasL might restrain the negative effects of efferocytosis on macrophage activation. Second, anti-FasL would help immunity by rescuing effector CD8 T cells, which either activate or kill macrophages from T. cruzi-infected mice. Although we have evidence of both cytotoxic activity and IFN-γ production by CD8 T cells, the effects of anti-FasL on macrophage phenotype do not correlate with higher IFN-γ levels or with increased macrophage viability or with reduced cytotoxicity. It is worth investigating whether blockade of apoptosis promotes heightened effector activities by antigen-specific CD8 T cells in vivo and how treatment with anti-FasL or zVAD affects distinct subsets of effector cells. Importantly, perforin-and IFN-γ-expressing subsets of CD8 T cells might have opposing (pathogenic versus protective) roles in Chagas disease. 18 Our results are compatible with the hypothesis that inhibition of CD8 T-cell apoptosis potentiates macrophage-mediated immunity by restraining the inhibitory effects of efferocytosis on macrophages. First, apoptotic cells have direct effects on macrophages and on infected mice to promote parasite, 25, 28, 46 bacterial, [47] [48] [49] [50] and viral 51 infections. Second, efferocytosis changes macrophage function by inducing distinct metabolic programs 28, 50 and production of soluble factors. 28, [48] [49] [50] Efferocytosis induces secretion of TGF-β, 28 which suppresses induced-nitric oxide synthase expression (Supplementary Figure S4) and NO production 28 upon LPS and/or IFN-γ stimulation. Third, the effects of apoptotic cells can be reverted by interfering with the uptake of apoptotic cells, the metabolic activity, or the production of soluble mediators. 28, 48, 49 Nonetheless, it is noteworthy that either activation or suppression of immune responses ensues when efferocytosis is mediated by dendritic cells 52, 53 or by macrophages phagocytosing apoptotic cells, depending on the genetic background/the immune features of cells 46 or infections. 50, 53, 54 Recent findings suggest that macrophages use different sets of receptors to efferocytose under homeostatic or inflammatory conditions. 55 The experimental model of Chagas disease provides an opportunity to investigate how different receptors are involved in efferocytosis and modulation of macrophage phenotype under the inflammatory setting of T. cruzi infection as well as how this will affect the development of disease. Whereas M1 macrophages might promote inflammation, M2 macrophages can induce fibrosis in the heart 56 in the context of parasite infection. Here we show that whereas effector CD8 T cells might contribute to the inflammatory environment in tissues, apoptosis of CD8 T-lymphocytes counterbalances macrophage activation, negatively affecting immunity to T. cruzi infection, by promoting macrophage differentiation towards an M2-like phenotype. Moreover, pharmacologic tools that target apoptosis are able to restore M1-macrophage responses, opening new avenues to promote immunity to infectious diseases.
Materials and Methods
Mice and T. cruzi infection. BALB/c mice were obtained from the Fluminense Federal University (UFF) or from the Oswaldo Cruz Institute (FIOCRUZ) and maintained in the animal facility at the Federal University of Rio de Janeiro (UFRJ). Male BALB/c mice, aged 6-8 weeks, were infected intraperitoneally with 2 × 10 5 metacyclic trypomastigotes of Dm28c T. cruzi clone, obtained by chemically induced metacyclogenesis in triatomine artificial urine-proline medium. 33 Experiments were conducted during acute (18-22 days post infection (dpi)) infection and age-matched BALB/c mice were used as uninfected controls. All procedures were approved (protocol IBCCF178) by the University's Ethical Committee for Animal Experimentation (UFRJ), according to national and institutional regulations that comprise with international standards.
Flow cytometry assays. PECs or cultured cells were washed in FACS buffer (plus 2% FCS), followed by incubation with anti-CD16/CD32 (eBioscience, San Diego, CA, USA) for Fc blocking. We stained cells with anti-CD8, anti-CD5, anti-CD19, anti-B220, anti-F4/80 mAbs, anti-CD11b, and anti-CD11c (clone HL3) labeled with PE, FITC, or allophycocyanin (BD Biosciences, Chicago, IL, USA), or with FITC-labeled anti-Ly6G (clone 1A8), allophycocyanin-labeled anti-Ly6C (clone HK1.4), or anti-CD4 mAbs (eBioscience), or with Alexa Fluor 488-labeled anti-MGL1 (CD301a) mAb (AbD Serotec, Kidlington, UK) or control rat IgG2a mAb (R&D Systems, Minneapolis, MN, USA). For intracellular staining, we washed, permeabilized, and stained cells with PE-labeled anti-IL-12p35 or control murine IgG1 mAb (R&D Systems). For IL-12p35 (M1) and MGL1 (M2) subsets, gates were based on the exclusion of background staining with isotype control mAbs. We then washed, fixed, and acquired cells with the CellQuest software on a FACSCalibur system (BD Biosciences). For apoptosis detection, cells were first stained with allophycocyanin anti-CD8, washed, and then treated with FITC-annexin V (BD Biosciences) for 20 min at room temperature, according to the manufacturer; 7-AAD (eBioscience) was added just before flow cytometry. For analysis, we used the FlowJow software (TreeStar, Ashland, OR, USA).
Microscopy. Upon cytospining, PECs were fixed in a glass layer with 4% paraformaldehyde, followed by staining with Alexa Fluor 488-labeled anti-MGL1, PE-labeled anti-CD8, and DAPI (4′,6-diamidino-2-phenylindole, dihydrochloride; Invitrogen Life Technologies, Carlsbad, CA, USA) for nuclear staining. For immunofluorescence, images were captured with an Imager M2 ApoTome microscope (Zeiss, Oberkochen, Germany) or with an EVOS fl (AMG -Advanced Microscopy Group, Bothell, WA, USA). For optical microscopy, PECs from infected mice were stained with the Panoptic Staining Kit (Laborclin, Pinhais, Brazil). The images were acquired with an Olympus BX51 microscope (Olympus Optical Co., Tokyo, Japan) and an Olympus 72 digital camera (Olympus Optical Co.).
Peritoneal exudates and cell cultures. PECs were collected in 3-5 ml of DMEM (Invitrogen Life Technologies), supplemented with 2 mM glutamine, 5 × 10 5 M 2-ME, 10 μg/ml gentamicin, 1 mM sodium pyruvate, and 0.1 mM MEM nonessential amino acids (culture medium). Upon centrifugation, supernatants were collected for cytokine assays. PECs were processed for flow cytometry and cultures. PECs (1 or 1.5 × 10 6 cells) were added to 24-well vessels and maintained in culture medium plus 10% FCS (Invitrogen Life Technologies) during 2-3 h and then gently washed to remove the excess of non-adherent cells, but retain CD8 T cells (30-40% of cells recovered from 24 h supernatants washed from cultures). Other non-adherent PECs are about 14-20% of B cells, 5-7% CD4 T cells, 1-2% CD11c + , and 1-4% Ly6G + cells. Cultures enriched in T cells (70-80% CD8 T cells recovered from culture supernatants) were obtained by culturing PECs on platebound anti-CD8 (53-6.7) mAb or anti-CD3 (145-2C11) mAb (10 μg/ml; BD Biosciences) during 2 h before washing out non-adherent cells. The remaining cells were maintained in culture medium plus 10% FCS at 37°C and 7% CO 2 in a humid atmosphere. Some cultures also received T. cruzi Ag (lysates of 1 × 10 6 metacyclic parasites per well). These mixed cultures were treated or not with 10 μg/ml of antiFasL (MFL3) mAb or control IgG mAb (eBioscience), or with 40 μM of zVAD (BD Biosciences) or 0.2% DMSO (Sigma, St Louis, MO, USA). After 48 h, we collected supernatants for cytokine assays or mixed supernatants with equal volumes of the Griess reagent (1% sulfanilamide, 0.1% naphthylethylenediamine dihydrochloride, 2% H 3 PO 4 ; Sigma) to determine NO production. The absorbance was measured at 540 nm and results are expressed as the content of nitrites, based on the concentration of sodium nitrite solutions as standard. After washing out non-adherent cells, macrophages were evaluated for viability by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide from Sigma) assay or detached with 2 mM EDTA (plus 2% FCS) at 4°C and processed for flow cytometry, as above. /well) in 24-well vessels. Cocultures were treated with 1 ng/ml IL-2 (BD Biosciences) to prevent spontaneous death 22 and incubated with soluble anti-CD3 (5 μg/ml). Cocultures were then treated or not with anti-FasL (10 μg/ml) or control IgG mAb and maintained at 37°C and 7% CO 2 humid atmosphere during 48 h. Supernatants were collected for NO and cytokine assays. Lymphocytes were processed for apoptosis assays. Trypomastigotes released from infected macrophages were counted in culture supernatants after 2-4 weeks of infection.
Treatment with anti-FasL. For in vivo inhibition of apoptosis, infected mice were injected intraperitoneally with 100 μg of anti-FasL (MFL3 clone) mAb or control hamster IgG mAb (eBioscience) at 18 dpi. After 3 days, PECs were recovered with 4 ml of culture medium and centrifuged. Supernatants were kept for cytokine assays and PECs were processed for flow cytometry or cultured in 48-well vessels and infected or not with metacyclic trypomastigotes, as described above.
Adoptive transfer of T cells. T-cell suspensions (5 × 10 6 /ml) from normal and infected (20 dpi) mice were stimulated in vitro with plate-bound anti-CD3 (10 μg/ml) in the presence of zVAD (40 μM) or 0.2% DMSO (control vehicle) during 4 or 24 h. After 4 h, T cells from infected mice were recovered from the plates, washed to remove zVAD or DMSO, and injected intraperitoneally (2 × 10 6 /0.4 ml) in infected mice (20 dpi). T cells that remained in cultures during 24 h were assayed for apoptotic CD4 and CD8 T cells. After 2 days, PECs were recovered from mice with 3 ml of DMEM. Upon centrifugation, supernatants were kept for cytokine assays and PECs were cultured in 48-well vessels and infected or not with metacyclic trypomastigotes, as described above. For flow cytometry, suspensions containing 1 × 10 6 PECs were treated with 50 ng/ml of phorbol myristate acetate (PMA) (Sigma), 1 μg/ml of ionomycin (Sigma), and 1 μg/ml brefeldin (Golgiplug; BD Biosciences) in propylene tubes during 3 h before staining.
Cytokine assays. Culture supernatants or diluted peritoneal exudates were used for cytokine and chemokine assays by sandwich ELISA, by using pairs of specific mAbs (R&D Systems or eBioscience), one of which was labeled with biotin, and developed with streptavidin-alkaline phosphatase (Invitrogen Life Technologies) and with p-nitrophenyl phosphate (Thermo Scientific Pierce, Waltham, MA, USA) as substrate. Cytokine levels were also analyzed in fresh supernatants by chemiluminescence arrays (Proteome Profiler -Mouse Cytokine Array Panel A Array Kit, R&D Systems), according to the manufacturer's instructions.
Statistics. All tests were performed, by using the GraphPad Prism (v. 6.0). Results are expressed as average and S.E.M. in figures. The number (N) of animals per group is indicated in figure legends. For parasite load, data were transformed to log of parasites per ml for statistical analysis. Data were analyzed by KolmogorovSmirnov test for assessing normal distribution and by unpaired Student's two-tailed t-test or ANOVA, followed by Dunnett's or Tukey's post-test. Significant differences are indicated for Po0.05 (*), Po0.01 (**), Po0.001 (***), and Po0.0001 (****). For in vitro experiments, data are expressed as the average of technical replicates per treatment and S.E.M. When analyzing more than two groups or treatments, we performed ANOVA followed by Tukey's or Bonferroni post-test. Significant differences in t-tests and ANOVA are indicated as above.
